Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug ...

Gilead's chief executive calls lenacapavir a once in a decade medicine. The HIV treatment could push Gilead stock further up ...

The firm highlighted that Gilead's shares have seen a rise due to positive developments in its pipeline, particularly for Lenacapavir in HIV prevention and anito-cel in multiple myeloma.

The firm highlighted that Gilead's shares have seen a rise due to positive developments in its pipeline, particularly for Lenacapavir in HIV prevention and anito-cel in multiple myeloma. Gilead's ...

Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year.  | For ...

Addressing stigma, inequity, and access to HIV innovations remains critical to progress in the global HIV response, says IAS ...

Promising new drugs to prevent and treat HIV have the potential to transform the response to the disease. But getting these ...

Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention drug Lenacapavir (PrEP) and next-gen HIV ...

Lenacapavir (previously GS-6207) is the first in a new class of class HIV-1 capsid inhibitor that Gilead is hoping will eventually free patients from the need to take daily oral tablets, although ...

Morgan Stanley upgraded Gilead (GILD) to Overweight from Equal Weight with a price target of $113, up from $87. The firm sees ...

Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence Flynn ...